SAB Biotherapeutics, Inc. (SABS) - 10-K Summary
Business Context and Reporting Period
Company: SAB Biotherapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: SAB is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) using a proprietary platform involving transchromosomic cattle (Tc Bovine). The company's lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) designed to prevent or delay the progression of Type 1 Diabetes (T1D). The company has no commercially approved products and generates revenue primarily through government grants.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $1.32 million | $2.24 million |
| Net Loss | $(34.11) million | $(42.19) million |
| Operating Expenses | $44.23 million | $40.31 million |
| Cash & Cash Equivalents | $8.90 million | $56.57 million |
| Short-Term Investments | $11.86 million | $0 |
| Total Liquidity | $20.76 million | $56.57 million |
| Warrant Liabilities | $6.39 million | $11.77 million |
Note: The company reported a non-cash gain of $5.39 million related to the change in fair value of warrant liabilities, which significantly reduced the reported net loss compared to operating performance.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 40.9% ($0.92 million) due to the termination of the JPEO Rapid Response Contract and the completion of NIH-NIAID grants. The company does not anticipate pursuing additional funded research outside its primary T1D focus.
- R&D Expense Surge: Research and development expenses increased by 83.2% ($13.7 million) to $30.25 million. This was driven by a 415% increase in clinical trial expenses ($3.4 million) and a 479% increase in outside laboratory services ($4.7 million) as the company advanced SAB-142.
- G&A Expense Reduction: General and administrative expenses decreased by 41.3% ($9.8 million) to $13.98 million, primarily due to a $7.5 million decrease in non-capitalized financing costs and a reduction in administrative support fees.
- Liquidity Position: Cash and cash equivalents dropped significantly from $56.6 million to $8.9 million, while the company invested $11.9 million in short-term securities. Total liquidity remains at approximately $20.8 million.
Guidance, Outlook, and Risks
Clinical Progress: On January 28, 2025, the company announced positive topline Phase 1 results for SAB-142, showing a favorable safety profile with zero serum sickness and zero anti-drug antibodies. The company plans to advance SAB-142 into a Phase 2b trial (SAFEGUARD study) in mid-2025.
Going Concern Warning: Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern. The company expects to incur losses for the foreseeable future and states that existing resources will not be sufficient to cover operating cash needs for more than 12 months from the issuance of the financial statements. Additional equity or debt financing is required.
Key Risks:
- Capital Requirements: Failure to secure additional funding could force the company to scale back operations, reduce headcount, or cease operations.
- Regulatory Approval: Success depends on obtaining FDA approval for both the therapeutic antibody and the genetically modified animals (New Animal Drug Application), a complex and uncertain process.
- Manufacturing: Reliance on a proprietary animal production platform introduces risks related to herd health, disease outbreaks, and scaling capabilities.
- Warrant Liability Volatility: Financial results are subject to significant non-cash fluctuations based on the fair value of warrant liabilities.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the "substantial doubt" going concern warning and the drop in cash reserves to under $9 million.
- Phase 2b Timeline: Confirm the initiation date and enrollment progress of the SAFEGUARD Phase 2b trial scheduled for mid-2025.
- Warrant Liability Impact: Assess the sensitivity of future earnings to changes in the fair value of the $6.4 million warrant liability.
- Grant Revenue Sustainability: Evaluate the likelihood of securing new government grants, as the company has indicated it will not pursue funded research outside of T1D.
- Manufacturing Capacity: Review the status of the Tc Bovine herd and the capacity of the Sioux Falls facilities to support Phase 2b and potential commercial scale-up.